Brokerages Set Organon & Co. (NYSE:OGN) PT at $11.40

Organon & Co. (NYSE:OGN) has earned a consensus rating of “Reduce” from the seven research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $11.40.

Separately, Weiss Ratings downgraded Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC raised its position in Organon & Co. by 87.8% during the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after acquiring an additional 2,033 shares in the last quarter. Allied Private Wealth LLC acquired a new position in shares of Organon & Co. during the 2nd quarter worth about $33,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Organon & Co. during the 4th quarter worth about $44,000. Kestra Advisory Services LLC bought a new stake in shares of Organon & Co. in the 4th quarter valued at about $47,000. Finally, WNY Asset Management LLC bought a new stake in shares of Organon & Co. in the 1st quarter valued at about $64,000. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Up 0.1%

Shares of OGN stock opened at $13.77 on Monday. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of 17.88, a P/E/G ratio of 1.27 and a beta of 1.55. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.77. The firm has a fifty day moving average of $13.58 and a 200-day moving average of $11.12. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $0.02 per share. The ex-dividend date is Friday, August 14th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s dividend payout ratio is presently 10.39%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.